$CNK

Cavalier Michael sold (to issuer) $3.8M of CNK (indirect holdings)

Cavalier Michael (EVP-General Counsel) sold (to issuer) 107,296 indirectly-held shares of Cinemark Holdings, Inc. (CNK) at $35.02 ($3.76M total) on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cavalier Michael
Published Sep 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 7:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CNK
Neutral
medium confidence
Mentioned
$CNK
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CNKNeutralLow
01

Why it matters

The sale reduces insider ownership but does not alter control; market may view it as neutral.

02

Market read

Primary insider sale filing; modest relevance for short‑term traders.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 5/10Novelty 6/10Timing: same‑day filing (2026‑09‑03)

Background

Form 4 filings disclose insider transactions; investors monitor them for sentiment cues.

Company-level read

Ticker impact

$CNKNeutralMedium confidence
Context

EVP-General Counsel sold 107,296 shares for $3.76M via 10b5-1 plan, reducing holdings to 223,385 shares.

Expected impact

Potential slight downward pressure in short term; limited long‑term effect.

Evidence & confidence

The transaction is a primary Form 4 filing, sizable for an insider but not material enough to drive a large move.

Market effects

Minimal impact on entertainment/theater sector; insider sales are routine.

No significant regional effect.

Limited relevance beyond Cinemark investors.

Counterpoint

The sale could be a routine liquidity event rather than a negative signal.

Key entities

  • Cavalier Michael

    EVP‑General Counsel of Cinemark Holdings, reporting the sale.

  • Cinemark Holdings, Inc.

    US‑listed theater operator (ticker CNK).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMCMedAI 8/10

AMC vs. Cinemark: Which Theater Stock Is the Better Buy Now?

AMC and Cinemark reported record Q2 earnings, with AMC's revenue up 14.2% and Cinemark's surpassing $1B. Both benefit from strong box office trends but face challenges like high costs and debt. AMC's leverage is above target, while Cinemark's performance depends on movie releases and rising electricity costs. Analysts expect strong growth for both, with Cinemark showing slightly better financial strength and growth prospects.

$WBDLow

Warner Bros. Discovery Merger

Cinemark, a Texas-based theater operator, now supports the $110.8B Paramount-Warner Bros. Discovery merger, citing benefits for the box office and industry. AMC and Regal also back the deal, but California and the WGA oppose it, with a trial set for 2027.

$PARAMed

An Offer They Can’t Refuse: Theater Execs Split on Whether to Join Paramount-Warner’s Merger Movement

Paramount Skydance is seeking theater-industry support for its merger with Warner Bros. Discovery amid a legal fight with 12 state attorneys general. Regal and Vue CEOs backed the deal, citing David Ellison’s pledge to release 30 films a year. Paramount reportedly offered contracts for 30 films for at least three years, plus windowing terms and possible penalties.

$CNKMed

Cinemark Holdings, Inc. (CNK): Results of Operations and Financial Condition

Cinemark Holdings, Inc. (CNK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CINEMARK HOLDINGS, INC. REPORTS SECOND QUARTER 2026 RESULTS Generated all-time high quarterly revenue of $1.1 billion with records across all major revenue categories Delivered Net Income of $141 million, an increase of nearly 50% year-over-year Achieved our highest

$IMAXMed

Nolan’s ’The Odyssey’ eyes $200M global debut, benefiting IMAX and theater stocks By Investing.com

Christopher Nolan’s “The Odyssey” is set to open in theaters Friday with a projected $200M worldwide debut. Variety projects $90M to $100M domestic opening across 3,900 North American theaters. IMAX (IMAX) benefits from limited IMAX 70mm capacity. AMC (AMC) got a July 15 upgrade to Buy with a $3.00 target. Marcus (MCS) and Cinemark (CNK) may also gain. IMAX Q2 2026 earnings are due July 23.